Intellia Therapeutics Croissance future

Future contrôle des critères 3/6

Intellia Therapeutics devrait augmenter ses bénéfices et son chiffre d'affaires de 26.4% et de 67.2% par an respectivement. Le BPA devrait croître de de 32.8% par an. Le rendement des capitaux propres devrait être 68.7% dans 3 ans.

Informations clés

26.4%

Taux de croissance des bénéfices

32.8%

Taux de croissance du BPA

Biotechs croissance des bénéfices	37.0%
Taux de croissance des recettes	67.2%
Rendement futur des capitaux propres	68.7%
Couverture par les analystes	Good
Dernière mise à jour	20 Nov 2024

Mises à jour récentes de la croissance future

Pas de mise à jour

Recent updates

Prévisions de croissance des bénéfices et des revenus

LSE:0JBU - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	74	-616	-472	-454	19
12/31/2025	52	-569	-444	-434	29
12/31/2024	53	-529	-400	-363	29
9/30/2024	43	-522	-363	-357	N/A
6/30/2024	46	-509	-383	-373	N/A
3/31/2024	53	-486	-418	-405	N/A
12/31/2023	36	-481	-408	-394	N/A
9/30/2023	52	-462	-407	-391	N/A
6/30/2023	53	-453	-384	-368	N/A
3/31/2023	53	-430	-379	-363	N/A
12/31/2022	52	-474	-392	-333	N/A
9/30/2022	51	-442	-355	-298	N/A
6/30/2022	45	-400	-342	-285	N/A
3/31/2022	38	-369	-309	-252	N/A
12/31/2021	33	-268	-238	-225	N/A
9/30/2021	27	-229	-221	-211	N/A
6/30/2021	42	-185	-181	-174	N/A
3/31/2021	52	-149	-69	-64	N/A
12/31/2020	58	-134	-53	-50	N/A
9/30/2020	62	-120	-43	-38	N/A
6/30/2020	51	-116	-41	-35	N/A
3/31/2020	46	-109	-126	-120	N/A
12/31/2019	43	-100	-110	-103	N/A
9/30/2019	40	-90	-89	-83	N/A
6/30/2019	37	-89	-76	-70	N/A
3/31/2019	33	-86	-71	-65	N/A
12/31/2018	30	-85	-68	-61	N/A
9/30/2018	29	-90	-81	-74	N/A
6/30/2018	29	-83	N/A	-78	N/A
3/31/2018	27	-76	N/A	-72	N/A
12/31/2017	26	-68	N/A	-65	N/A
9/30/2017	25	-54	N/A	-58	N/A
6/30/2017	23	-46	N/A	-49	N/A
3/31/2017	21	-38	N/A	34	N/A
12/31/2016	16	-32	N/A	36	N/A
9/30/2016	13	-26	N/A	45	N/A
6/30/2016	9	-22	N/A	49	N/A
3/31/2016	7	-18	N/A	-16	N/A
12/31/2015	6	-12	N/A	-2	N/A
9/30/2015	4	-14	N/A	1	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: 0JBU devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: 0JBU devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: 0JBU devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de 0JBU ( 67.2% par an) devrait croître plus rapidement que le marché UK ( 3.5% par an).

Croissance élevée des revenus: Le chiffre d'affaires de 0JBU ( 67.2% par an) devrait croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de 0JBU devrait être très élevé dans 3 ans ( 68.7 %).

Intellia Therapeutics Croissance future

Future contrôle des critères 3/6

Informations clés

Mises à jour récentes de la croissance future

Recent updates

Intellia Therapeutics, Inc. Announces First Clinical Evidence from Ongoing Phase 1 Study That Nexiguran Ziclumeran (nex-z) May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

Third quarter 2024 earnings released: US$1.34 loss per share (vs US$1.38 loss in 3Q 2023)

Intellia Therapeutics, Inc. Presents Positive Results from the Phase 2 Study of NTLA-2002

Intellia Therapeutics, Inc. Announces Initiation of Haelo Phase 3 Study of Ntla-2002

Second quarter 2024 earnings released: US$1.52 loss per share (vs US$1.40 loss in 2Q 2023)

New major risk - Revenue and earnings growth

Intellia Therapeutics, Inc. Receives Authorization to Initiate Phase 1/2 Clinical Trial of Ntla-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency

Blueallele Corporation Files Lawsuit for Patent Infringement Against Intellia Therapeutics, Inc., for the Unauthorized Use of Blueallele’S Patented Bi-Directional Insertion Templates

Intellia Therapeutics, Inc. Announces Chief Financial Officer Changes

Intellia Therapeutics, Inc. Announces Executive Changes

Intellia Therapeutics to Present the First-Ever Clinical Data from Patients Redosed with an Investigational in Vivo CRISPR Gene Editing Therapy At the Peripheral Nerve Society Annual Meeting 2024

Intellia Therapeutics, Inc. Names Brian Goff to its Board of Directors

Intellia Therapeutics, Inc. Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002

First quarter 2024 earnings released: US$1.13 loss per share (vs US$1.18 loss in 1Q 2023)

Intellia Therapeutics, Inc. to Report Q1, 2024 Results on May 09, 2024

Intellia Therapeutics, Inc., Annual General Meeting, Jun 12, 2024

Now 25% overvalued

Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 3 MAGNITUDE Study of NTLA-2001 as Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy

Intellia Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $375.727167 million.

New minor risk - Shareholder dilution

Full year 2023 earnings released: US$5.42 loss per share (vs US$6.16 loss in FY 2022)

New major risk - Revenue and earnings growth

Intellia Therapeutics, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Intellia Therapeutics, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine

President recently sold US$566k worth of stock

Intellia Therapeutics, Inc. Announces Resignation of John F. Crowley from the Board of Directors of Company and Its Committees

Third quarter 2023 earnings released: US$1.38 loss per share (vs US$1.49 loss in 3Q 2022)

New minor risk - Share price stability

Intellia Therapeutics, Inc. Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 At the 4th International ATTR Amyloidosis Meeting

Insufficient new directors

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Second quarter 2023 earnings released: US$1.40 loss per share (vs US$1.33 loss in 2Q 2022)

Intellia Therapeutics, Inc. Appoints Eliana Clark, Phd, Executive Vice President and Chief Technical Officer

Intellia Therapeutics, Inc. Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)

Intellia Therapeutics, Inc. Announces Resignation of Jean-François Formela as Board Member

First quarter 2023 earnings released: US$1.18 loss per share (vs US$1.97 loss in 1Q 2022)

Full year 2022 earnings released: US$6.16 loss per share (vs US$3.78 loss in FY 2021)

President recently sold US$248k worth of stock

Intellia Therapeutics Presents New Interim Data from First-In-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)

Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001

Third quarter 2022 earnings released: US$1.49 loss per share (vs US$0.97 loss in 3Q 2021)

Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 ACAAI Annual Scientific Meeting

Intellia Therapeutics Announces Positive Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)

Intellia Therapeutics, Inc. Receives U.S. FDA Orphan Drug Designation for NTLA-2002, an Investigational CRISPR Therapy for the Treatment of Hereditary Angioedema

Intellia Therapeutics, Inc. to Present Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema At the 2022 Bradykinin Symposium

Second quarter 2022 earnings released: US$1.33 loss per share (vs US$1.01 loss in 2Q 2021)

Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. Announces Additional Positive Interim Data from an Ongoing Phase 1 Study of Their Lead Investigational in Vivo Genome Editing Candidate, NTLA-2001

Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the International Liver Congress™ 2022

First quarter 2022 earnings released: US$1.97 loss per share (vs US$0.69 loss in 1Q 2021)

Intellia Therapeutics, Inc. Names Muna Bhanji to Its Board of Directors

Intellia Therapeutics, Inc., Annual General Meeting, Jun 14, 2022

Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2a Clinical Trial of NTLA-5001 for Treatment of Acute Myeloid Leukemia

Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Intellia Therapeutics, Inc. (NasdaqGM : NTLA) acquired Rewrite Therapeutics, Inc. for $200 million.

Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema

Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy

Third quarter 2021 earnings released: US$0.97 loss per share (vs US$0.47 loss in 3Q 2020)

Intellia Therapeutics, Inc. announces U.S. Food and Drug Administration accept the investigational new drug (IND) application for NTLA-5001

Second quarter 2021 earnings released: US$1.01 loss per share (vs US$0.61 loss in 2Q 2020)

Intellia Therapeutics, Inc.(NasdaqGM:NTLA) dropped from Russell 3000E Index

Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2021 Peripheral Nerve Society Annual Meeting

First quarter 2021 earnings released: US$0.69 loss per share (vs US$0.63 loss in 1Q 2020)

Intellia Therapeutics, Inc. Announces the Presentation of New Data from Its CRISPR/Cas9 Platform

Intellia Therapeutics Presents Preclinical Proof of Concept for CRISPR-based In Vivo Editing of Bone Marrow at Keystone eSymposium

Full year 2020 earnings released: US$2.40 loss per share (vs US$2.11 loss in FY 2019)

Revenue misses expectations

Intellia Therapeutics, Inc. Achieves Normal Human Alpha-1 Antitrypsin Protein Levels in Non-Human Primates Through Targeted Gene Insertion for the Treatment of AAT Deficiency

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance